Wade Jeffrey L's Form 4 filing
Lexicon Pharmaceuticals, Inc.LXRX · filed Jun 20, 2023
- Accession no.
- 0001127602-23-018978
- Filed
- Jun 20, 2023
- Trade date
- Jun 20, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $28.1K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wade Jeffrey LCIK 0001225767 | Officer (President and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2023 | Common Stock | PPurchaseAcquired | +10,000 | $2.34 | +$23,400 | 252,341 | Direct | |
| Jun 20, 2023 | Common Stock | PPurchaseAcquired | +2,000 | $2.33 | +$4,660 | 254,341 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.